Invenomic Capital Management fully exited its position in Haemonetics Corporation (HAE 0.54%), according to a February 17, 2026, SEC filing, selling 498,317 shares previously worth $24.29 million.What happenedAccording to a February 17, 2026, SEC filing, Invenomic Capital Management sold its entire stake of 498,317 shares in Haemonetics Corporation. The net position change for the quarter was $24.29 million.What else to knowThe fund’s exit from Haemonetics Corporation reduced the position from 1.2% of 13F A ...

Core Insights - Haemonetics Corporation's Hospital business recovery is expected to drive growth in upcoming quarters, with strong adoption of the NexSys PCS system indicating long-term potential [1][9] - The company has a market capitalization of $2.82 billion and has consistently beaten earnings estimates over the past four quarters, with an average surprise of 6.8% [2] Haemonetics' Key Upsides - The NexSys PCS system, which is FDA-cleared, enhances plasma yield collections and improves productivity, resulting in a 16-minute reduction in donor door-to-door time on average [3] - The introduction of proprietary Persona Technology strengthens the NexSys PCS value proposition, contributing to margin expansion in Q3 FY26 [4] - The Hospital business is well-positioned for growth, with a 2% organic revenue increase through December 2025, driven by an 11% growth in Blood Management Technologies [5][6] Concerns for Haemonetics - The company has a long-term debt of $920 million and a debt-to-capital ratio of 50.2%, indicating solvency concerns [9][10] - Haemonetics operates in a highly competitive environment, which may impact revenue and profit if product adoption is slower than expected [11] - The Zacks Consensus Estimate for fiscal 2026 earnings remains at $4.95 per share, with revenues projected at $1.33 billion, reflecting a 2.6% decrease from the previous year [12]

Summary of Haemonetics Conference Call Company Overview - **Company**: Haemonetics - **Industry**: Medical Technology (MedTech) - **Revenue**: Approaching $1.4 billion, diversified small midcap MedTech company - **Market Leadership**: Global leader in plasma apheresis with a billion-dollar addressable market [2][3] Key Financial Performance - **Fiscal Year Performance**: - High single-digit revenue growth - Operating margin expansion of over 800 basis points - Cumulative free cash flow of $600 million to $700 million - Added $3 in earnings per share over the four-year long-range plan (LRP) [3] Plasma Business Insights - **Growth**: Plasma segment grew 3% organically, 20% excluding CSL [4] - **Drivers of Growth**: - Sustained share gains - Innovation-led platform benefits - Increased collection strength [5] - **Persona PLUS Launch**: - Mid-single digit yield increase compared to Persona - Built on data-driven approach with a pivotal trial involving over 30,000 plasma donations [6][8] Customer Relationships and Market Position - **Customer Engagement**: Strong relationships leading to share gains and deeper strategic partnerships [10] - **Market Leadership**: Expectation to grow global marketplace leadership for the foreseeable future [12] Competitive Landscape - **Competitors**: Mention of Terumo's Rika and other competitors, with emphasis on Haemonetics' integrated platform and lower cost metrics [13][14] - **NexSys and Persona PLUS**: Positive reception from customers, leading to standardization around Haemonetics' technology [10] Interventional Technologies and Vascular Closure - **Challenges**: Acknowledgment of challenges in the vascular closure space but confidence in returning to above-market growth [19][20] - **Market Dynamics**: Shift to Ambulatory Surgical Centers (ASCs) and increased adoption of PFA expected to favor Haemonetics [21] - **Product Launches**: - MVP label expansion in the U.S. and Japan - Vivasure acquisition leading to the launch of PerQseal Elite [21][27] Blood Management Technologies - **Growth Potential**: Blood management technologies, particularly TEG, showing consistent double-digit growth with significant market penetration opportunities [33][34] - **Market Size**: Global Serviceable Available Market (SAM) for TEG estimated at over $400 million, with less than 50% penetration [34] Capital Deployment Strategy - **Focus on Organic Growth**: Prioritizing R&D and commercial execution for competitive advantage [43] - **Debt Management**: Addressed $300 million debt maturity using revolver, maintaining capital structure efficiency [44] - **Share Repurchases**: Attractive risk-adjusted returns at current share prices, with plans for opportunistic capital deployment [44] Margin Improvement - **Current Margins**: Operating income margin increased from 13% to 26% over the past decade, with aspirations for further improvement [48][49] - **Future Expectations**: Anticipation of continued margin expansion driven by operational improvements and product mix [49] Outlook for FY27 - **Growth Expectations**: Balanced, sustainable growth with continued revenue growth, margin expansion, and free cash flow [53] Conclusion - **Company's Position**: Haemonetics is positioned for future growth with a strong focus on innovation, customer relationships, and market leadership in plasma and blood management technologies [55]

Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology [Accessibility Statement] Skip Navigation--BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS® Plasma Collection System with Persona® PLUS technology. Persona PLUS represent ...

Group 1 - Haemonetics Corporation will participate in the Raymond James 47th Annual Institutional Investors Conference on March 2, 2026, with a fireside chat led by President and CEO Chris Simon [1] - The event will be accessible via a live webcast on Haemonetics' Investor Relations website, with a replay available 12 hours post-event for 90 days [1] - Haemonetics is a global medical technology company focused on improving healthcare quality, effectiveness, and efficiency through innovative solutions [1] Group 2 - The company offers a range of hospital technologies aimed at enhancing patient care standards and outcomes [1] - Haemonetics provides end-to-end plasma collection technologies to optimize operations for plasma centers [1] - The company also supplies products that enable blood centers to collect essential blood components [1]

Haemonetics Corporation (NYSE:HAE) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81 Haemonetics Corporation (NYSE:HAE) is among the most innovative healthcare stocks. TheFly reported on February 6 that Baird lowered its price target for HAE to $81 from $99 while maintaining an Outperform rating. The firm updated its model following the company’s Q3 results and lowered the estimate ...

Core Insights - U.S. small-cap equities experienced modest gains in Q4 2025, supported by a positive macroeconomic backdrop and attractive valuations [1] - The Aristotle Small Cap Equity Fund (Class I-2) returned 1.96% in Q4 2025, slightly trailing the Russell 2000 Index's return of 2.19% [1] - Security selection positively impacted overall performance, while allocation effects detracted from it [1] Company Focus: Haemonetics Corporation - Haemonetics Corporation (NYSE:HAE) is recognized as a leading contributor to the Aristotle Small Cap Equity Fund, noted for its innovative medical technology solutions [2][3] - As of February 13, 2026, Haemonetics' stock closed at $57.76 per share, with a one-month return of -19.97% and a 12-month decline of 7.38% [2] - The company has a market capitalization of approximately $2.68 billion [2] - Haemonetics reported strong earnings that exceeded analyst expectations, bolstered by its competitive position in the plasmapheresis market and increased investment in R&D [3] - In Q3, Haemonetics reported revenue of $339 million, bringing the year-to-date total to $988 million [4]

Core Viewpoint - The performance of Haemonetics' international operations is crucial for assessing its financial resilience and growth prospects, especially in the context of a highly interconnected global economy [2][3]. Group 1: Financial Performance Overview - For the quarter ended December 2025, Haemonetics reported total revenue of $338.97 million, reflecting a decline of 2.8% year over year [4]. - The company is projected to achieve total revenue of $1.32 billion for the full year, indicating a fall of 2.6% from the previous year [9]. Group 2: International Revenue Breakdown - Japan contributed $18.14 million, or 5.4% of total revenue, with a surprise increase of +1.87% compared to analyst expectations [5]. - Europe generated $48.28 million, accounting for 14.2% of total revenue, surpassing projections by +6.65% [6]. - Other International regions contributed $1.81 million, making up 0.5% of total revenue, which was a decline of -22.23% from expectations [7]. Group 3: Future Revenue Expectations - Analysts anticipate revenues of $336.54 million for the current fiscal quarter, representing an increase of 1.8% year over year [8]. - Expected revenue contributions for the current quarter are projected to be 5.6% from Japan ($18.94 million), 13.5% from Europe ($45.38 million), and 1.2% from Other International ($3.93 million) [8].

Core Insights - Haemonetics reported third-quarter revenue of $339 million, with a year-to-date revenue of $1.1 billion, reflecting a 1% decline in organic revenue for the quarter but a 2% increase year to date, driven by growth in Blood Management Technologies (BMT) and offset by declines in Interventional Technologies (IVT) [1][4][6] Financial Performance - Adjusted earnings per share (EPS) increased by 10% to $1.31 in the quarter and 11% year to date to $3.67, with full-year adjusted EPS guidance raised to $4.90 to $5.00 per share [2][5] - The company raised its fiscal 2026 revenue guidance to a decline of 1% to 3% (previously 1% to 4%) and increased organic revenue guidance excluding CSL to growth of 8% to 10% (previously 7% to 10%) [2][6] Segment Performance - BMT grew 8% in the quarter and 11% year to date, driven by strong sales in hemostasis management and the adoption of new products like the TEG 6s disposable and heparinase neutralization cartridge [7][11] - IVT revenue declined 12% in the quarter and 8% year to date, primarily due to weaknesses in esophageal cooling and OEM-related challenges [6][8] Cash Flow and Margins - The company generated $74 million in free cash flow for the quarter, with year-to-date free cash flow reaching $165 million, and raised full-year free cash flow guidance to $200 million to $220 million [16][17] - Adjusted gross margin was reported at 60.2% for the quarter, reflecting a 250 basis point improvement year over year, attributed to technology adoption and divestitures [14][15] Strategic Initiatives - Haemonetics acquired Vivasure for $61 million, enhancing its vascular closure portfolio and targeting a market estimated at $300 million [19] - The company emphasized ongoing share gains and pricing benefits from new technology rollouts, with collection volumes exceeding seasonal expectations [17]

Core Viewpoint - Haemonetics Corporation reported strong earnings for Q3, exceeding analyst expectations in both earnings per share and sales figures, despite a subsequent decline in share price [1]. Financial Performance - The company reported quarterly earnings of $1.31 per share, surpassing the analyst consensus estimate of $1.25 per share [1]. - Quarterly sales reached $338.967 million, exceeding the analyst consensus estimate of $331.616 million [1]. - Haemonetics raised its FY2026 adjusted EPS guidance from a range of $4.80-$5.00 to $4.90-$5.00 [1]. Stock Performance - Following the earnings announcement, Haemonetics shares fell by 6%, trading at $61.13 [1]. Analyst Ratings and Price Targets - Barrington Research analyst Michael Petusky maintained an Outperform rating on Haemonetics and raised the price target from $93 to $94 [3]. - Mizuho analyst Anthony Petrone also maintained an Outperform rating but lowered the price target from $90 to $80 [3].